Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Parasol group recommended reduction in proteinuria over 24 months as a surrogate endpoint for full approval of FSGS drugs.
-
L’approbation de la FDA permet une distribution sans restriction d’EGRIFTA SVMD, levant ainsi l'incertitude concernant tous les lots fabriqués L’approbation du PAS fait suite à l’approbation...
-
FDA action allows for unrestricted distribution of EGRIFTA SV®, removing uncertainty with respect to all manufactured batches PAS approval follows recent FDA approval of new formulation, EGRIFTA...
-
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study
-
Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome
-
ST. LOUIS, April 02, 2025 (GLOBE NEWSWIRE) -- Curium announced today that the U.S. Food and Drug Administration approved its generic version of the Kit for the Preparation of Technetium Tc 99m...
-
Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term StabilityUrcosimod stable in single-use ampoules for more than 2½ yearsFDA requires drug to show long-term...
-
27 MARCH 2025 PRESS RELEASE Urteste plans to start clinical trials for its pancreatic cancer test in Europe in Q3 2025 Gdańsk, Poland – 27 March 2025 – Urteste S.A. (Warsaw Stock...
-
Arlington, VA, March 26, 2025 (GLOBE NEWSWIRE) -- AAMI is pleased to announce that the FDA has amended its database of Recognized Consensus Standards, adding multiple AAMI documents in the agency’s...
-
Pleco Therapeutics announces positive FDA feedback on PTX-252, supporting IND pathway for its novel AML treatment.